gcnt4 Antibody

What is GCNT4 and what is its significance in cancer research?

GCNT4 is a member of the glucosaminyl (N-acetyl) transferases family that has been implicated in multiple human malignancies. It functions as a key mediator of mucin core structure synthesis, branching, and oligomerization . Research has shown that GCNT4 is significantly downregulated in gastric cancer compared to normal gastric mucosa, suggesting its potential role as a tumor suppressor . GCNT4 regulates the cell cycle, particularly affecting the G2/M checkpoint, and its expression correlates with tumor depth, nervous invasion, and pathological TNM stage in gastric cancer .

Which antibodies are recommended for GCNT4 detection in research?

When selecting antibodies for GCNT4 detection in research applications, antibodies from established suppliers such as Sigma-Aldrich have been successfully employed in published studies. The anti-GCNT4 antibody (#138788) from Sigma-Aldrich has been validated for Western blotting applications in gastric cancer research . Researchers should ensure that selected antibodies are validated for their specific application requirements, whether for Western blotting, immunohistochemistry, or immunofluorescence.

What are the recommended protocols for GCNT4 Western blotting?

For optimal GCNT4 detection using Western blotting, cells should be lysed in RIPA buffer containing both phosphatase and protease inhibitors (such as those from Roche, Basel, Switzerland) . Protein concentration should be determined using a BCA Protein Assay Kit (Thermo Scientific). Sample preparation involves:

• Adding sample buffer to cell lysates and boiling at 95°C for 5 minutes

• Loading samples onto 12% SDS-PAGE gels and running at 80V for approximately 3 hours

• Electrophoretically transferring proteins to PVDF membranes (Millipore) for 2 hours

• Blocking membranes with 5% BSA for 30 minutes

• Incubating with primary anti-GCNT4 antibody at 4°C overnight

• Washing with 1% TBST three times

• Incubating with secondary antibodies (1:2000 dilution) for 1 hour

• Detecting using an ECL system (Thermo Fisher)

Protein expression levels should be normalized to GAPDH as a loading control .

How should researchers validate the specificity of GCNT4 antibodies?

Validating GCNT4 antibody specificity requires a multi-faceted approach:

• Perform Western blotting using positive controls (normal gastric tissue) and negative controls (gastric cancer cell lines with low GCNT4 expression)

• Conduct peptide competition assays where pre-incubation with the immunizing peptide should abolish specific signals

• Correlate antibody detection with mRNA expression data through parallel RT-qPCR

• Perform knockdown or overexpression experiments to confirm signal modulation

• Compare staining patterns across multiple antibodies targeting different epitopes of GCNT4

Cell lines with known GCNT4 expression profiles, such as GES-1 (high expression) and SGC-7901 or MGC-803 (low expression), serve as valuable controls for validation experiments .

What controls should be included when working with GCNT4 antibodies?

When designing experiments with GCNT4 antibodies, researchers should include the following controls:

• Positive tissue controls: Normal gastric mucosa with known high GCNT4 expression

• Negative tissue controls: Gastric cancer samples with known low GCNT4 expression

• Cell line controls: GES-1 (positive control) and MGC-803 or SGC-7901 (negative controls)

• Technical negative controls: Primary antibody omission or isotype control antibody

• Loading controls for Western blotting: GAPDH has been validated for this purpose

For immunohistochemistry, having multiple observers blinded to clinical data score the staining helps ensure reproducibility and minimize bias.

How can researchers troubleshoot weak or absent GCNT4 staining in immunohistochemistry?

When encountering weak or absent GCNT4 staining in immunohistochemistry, consider these troubleshooting approaches:

• Optimize antigen retrieval methods (test different buffers, pH levels, and heating times)

• Increase primary antibody concentration or extend incubation times

• Verify antibody integrity and storage conditions

• Assess tissue fixation quality and processing times

• Try alternative detection systems with higher sensitivity

• Include positive control tissues with known high GCNT4 expression in the same staining batch

Remember that approximately 67.3% of gastric cancer cases naturally show low GCNT4 expression (score 0-1.5), so weak staining may be biologically relevant rather than a technical issue .

How can discrepancies between GCNT4 mRNA and protein levels be explained?

Discrepancies between GCNT4 mRNA and protein levels, as observed in subcellular localization studies, may be explained by:

• Post-transcriptional regulation, including miRNA-mediated suppression

• Post-translational modifications affecting protein stability or degradation

• Differences in detection sensitivity between RT-qPCR and immunohistochemistry/Western blotting

• Subcellular compartmentalization (nuclear mRNA vs. cytoplasmic/membrane protein)

• Epigenetic regulation through methylation, which affects transcription but may not directly correlate with protein levels

To address these discrepancies, researchers should employ multiple detection methods and consider temporal aspects of gene expression and protein synthesis.

How can researchers assess GCNT4 methylation and its correlation with protein expression?

To investigate GCNT4 methylation and its correlation with protein expression:

• Analyze methylation status using bisulfite sequencing or methylation-specific PCR targeting the GCNT4 promoter region

• Quantify methylation levels and divide samples into terciles based on methylation intensity

• Perform parallel analysis of GCNT4 protein expression using Western blotting or immunohistochemistry

• Compare GCNT4 expression between hyper-methylated samples (third tercile) and unmethylated samples (first tercile)

• Treat cells with demethylating agents to confirm reversibility of methylation-induced suppression

TCGA gastric cancer dataset analysis has demonstrated that hyper-methylated samples exhibit lower GCNT4 expression compared to unmethylated samples, indicating methylation as a potential mechanism for GCNT4 downregulation .

What is the expression pattern of GCNT4 in gastric cancer versus normal tissue?

The expression pattern of GCNT4 shows significant differences between normal and cancerous gastric tissues:

This progressive decrease in GCNT4 expression from normal tissue to cancer suggests its potential role as a tumor suppressor in gastric cancer .

What clinicopathological features correlate with GCNT4 expression in gastric cancer?

GCNT4 expression correlates with several clinicopathological features in gastric cancer:

These correlations suggest that GCNT4 downregulation is associated with more aggressive disease characteristics .

What cell lines are recommended for GCNT4 overexpression or knockdown studies?

For GCNT4 expression manipulation studies, researchers should select cell lines based on baseline GCNT4 expression:

SGC-7901 and MGC-803 have been successfully used for GCNT4 overexpression experiments, with transfection efficiency verified by qRT-PCR and Western blotting .

How does GCNT4 affect cell cycle regulation in cancer cells?

GCNT4 plays a specific role in cell cycle regulation in gastric cancer cells. Overexpression experiments have revealed that GCNT4:

• Suppresses gastric cancer cell proliferation

• Induces cell cycle arrest specifically at the G2/M phase

• Attenuates the expression of G2/M regulators cdc25B and CyclinB1

• Does not affect G1/S phase-related molecules (P21, P27, P57, and CyclinD1)

Gene Set Enrichment Analysis (GSEA) of TCGA data further confirms the enrichment of G2/M checkpoint genes in samples with differential GCNT4 expression .

What are the best experimental approaches to study GCNT4's role in cancer progression?

To comprehensively study GCNT4's role in cancer progression, researchers should design experiments that:

• Modulate GCNT4 expression through overexpression in low-expressing gastric cancer cell lines and knockdown in normal gastric epithelial cells

• Perform flow cytometry analysis to quantify cell cycle distribution changes following GCNT4 manipulation

• Use Western blotting to detect alterations in cell cycle regulators (particularly G2/M checkpoint proteins)

• Conduct proliferation assays to measure growth effects

• Perform gene expression profiling to identify downstream targets

• Analyze methylation status and copy number variations as potential regulatory mechanisms

• Correlate in vitro findings with clinical data on tumor characteristics and patient outcomes

This multi-faceted approach allows researchers to connect molecular mechanisms to clinical significance .